Indaptus Therapeutics, Inc. Form 8-K Summary
Filing date: February 1, 2022. The filing reports the execution of an employment agreement between Intec Pharma Ltd., a wholly owned subsidiary, and Nir Sassi, the Company’s Chief Financial Officer.
Business Context and Reporting Period
The filing concerns an executive compensation arrangement and does not report quarterly or annual operating results. The agreement was entered into on February 1, 2022; the filing states that Mr. Sassi previously provided consulting services to the Company.
Financial and Compensation Information
- Annual base salary: $345,000, subject to potential upward annual review.
- Annual incentive opportunity: target bonus of up to 40% of base salary, based on individual and Company objectives established annually by the Board.
- Termination payment related to ending the prior consulting arrangement: $195,728.
- Potential equity awards: stock options or other equity awards may be granted from time to time, subject to Board approval.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material Changes Versus the Prior Comparable Period
Mr. Sassi’s consulting services agreement was terminated and replaced by an employment agreement. The filing does not provide prior-period compensation comparisons or quantify the Company’s historical consulting expense.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Either Intec or Mr. Sassi may terminate the employment relationship, subject to specified notice or cause requirements.
- If terminated without cause by Intec or for good reason by Mr. Sassi, he generally becomes eligible for severance equal to 12 months of base salary, plus a prorated performance-based bonus if earned.
- If qualifying termination occurs during the one-year period following a change in control or six months before one, additional benefits may include 12 months of base salary plus the annual target bonus, a prorated current-year bonus at target, and accelerated vesting of outstanding equity awards.
- Death or disability may entitle Mr. Sassi or his representatives to a prorated earned bonus based on predetermined performance goals.
- The agreement includes confidentiality, intellectual-property assignment, and expense-reimbursement provisions.
- The $195,728 consulting termination payment and potential change-in-control obligations are unusual compensation-related cash and equity commitments disclosed in the filing.
Key Facts for Investors to Verify
- Review the complete employment agreement, which the Company stated would be filed as an exhibit to its 2021 Form 10-K.
- Confirm the timing and accounting treatment of the $195,728 termination payment.
- Assess the potential cost of annual salary, target bonus, future equity awards, severance, and change-in-control benefits.
- Verify whether any equity awards have subsequently been approved or granted by the Board.
- Review subsequent filings for changes in Mr. Sassi’s employment status or additional compensation disclosures.